Drägerwerk AG & Co. KGaA. DRW8
July 24, 2012 - 7:38am EST by
genoa321
2012 2013
Price: 65.56 EPS $0.00 $0.00
Shares Out. (in M): 18 P/E 0.0x 0.0x
Market Cap (in $M): 1,300 P/FCF 9.5x 0.0x
Net Debt (in $M): 628 EBIT 0 0
TEV ($): 1,543 TEV/EBIT 0.0x 0.0x

Sign up for free guest access to view investment idea with a 45 days delay.

 

Description

Dräger is a “hidden champion” with market-leading niche products in the medical and safety technology industries trading at approximately 10x FCF (through the common shares: DRW8).

Dräger is a leading global provider of medical and safety technology based in Germany.  Approximately 60%, 20%, and 15% of revenue is from Europe, the Americas and Asia, respectively.  The Medical division’s acute point-of-care products are sold primarily to hospitals, whereas the Safety division’s gas detection and personal protection products have diversified end-markets including industrial, energy, mining, chemicals, utilities, and municipalities.

Strong positions in niche markets

Dräger products occupy powerful market positions (generally top 3 in Europe, US and worldwide; see exhibits A and B) in anesthesiology, respiratory care, neonatal care, medical monitoring/IT, gas detection systems, alcohol detection and firefighter breathing apparatus.  Dräger’s excellent competitive position is mentioned in Hermann Simon’s book, Hidden Champions of the 21st Century.

The Medical segment is in a strong competitive position despite competing against larger and more diversified competitors (e.g., GE, Phillips, and Covidien) as demonstrated by high, consistent market share in niche products and strong financial results (21% 10-year pre-tax return on capital).  Additionally, after the company terminated its relationship with Siemens, it did not experience a revenue decline (from fewer cross-selling opportunities).   The total addressable market should grow in the mid/high-single digits over the medium-term.

The Safety division is a gem: history of strong financial results (27% 10-year pre-tax return on capital, over the past 10 years EBIT increased 151% while capital employed only increased 23%) and market-leading niche products.  The €5bn total addressable market should grow in the high-single digits over the medium-term, driven by GDP growth and higher safety standards in developing countries.

Dräger has a significant moat from customer captivity and economies of scale in R&D

Dräger products are relied on to keep people alive.  With an average order of only €50-100k, the purely economic switching cost is insignificant compared to psychological and institutional switching costs manifested by the long-standing trust developed over many years (more than 120 years in some markets).  While not as broadly known as “Google” or “Xerox”, Dräger has a powerful brand/reputation (“draegerman” is synonymous with mine rescue staff member and “Dräger-Tubes” is synonymous for hazardous gas spot check).

Dräger invests heavily in its product offerings.  R&D is significant at 7% of sales, allowing the company to innovate and defend its market position.

Run for the long-term

Dräger has a long-term orientation that US investors are unaccustomed to seeing. The business is run by a fifth generation family member. The family owns 40% of the equity and controls the firm.

Family control is a red flag for many investors.  While there are legitimate risks, Dräger is a business that has survived five generations: it clearly has positive attributes.  Additionally, the family has the freedom to focus on long-term value creation, as opposed to distractions like quarterly performance and meeting estimates/guidance (“As a listed family company we don’t think in terms of quarters, but of decades” – Stefan Dräger).

Improving Capital Structure

In 2010, Dräger completed the purchase of Siemens’s 25% stake in Dräger Medical and subsequently converted Siemens’s cash-settled option to an equity-settled option.  The company then repurchased 41% of its outstanding participation certificates in April. Currently, Dräger has 10.2mm common shares (DRW8), 6.5mm preferred shares (DRW3), 1.3mm preferred share options outstanding (€64.12 strike; from Siemens transaction).  Additionally, the company has 0.8mm participation certificates outstanding.  At the current market prices and assuming dilution/exercise, the company has a €1.3bn market capitalization and €1.6bn enterprise value. Preferred shares currently trade at an approximate €10 premium to common shares due to the dividend structure (first €0.13 per share, €0.06 more than common) and greater liquidity.  

Risks & Limitations

  • Larger medical competitors bundling products
  • Dependent on capital spending (Medical division products have 5-10 year lifetime)
  • Trading illiquidity – 15,000 and 2,000 shares per day for DRW3 and DRW8, respectively
  • Short-term margin compression – after aggressive cost cutting program
  • Lack of a catalyst – family control reduces likelihood of a takeover, MBO, etc.

Valuation & Conclusion

Dräger Safety’s competitors have been active consolidating the already-consolidated space.  Acquisition multiples have averaged 11x EBITDA (see Exhibit C) and Mine Safety Appliances Company (NYSE: MSA), a direct competitor, trades at 9x EBITDA.

Using a sum-of-the-parts analysis, I estimate Dräger is worth €120 per share (see Exhibit F).  Dräger’s normalized free cash flow is over €7 per share, resulting in a 10% FCF yield through the common.  Dräger’s strong competitive positioning in growing, niche markets and a cheap valuation provides a significant margin of safety.

Exhibit A:  Products – Medical Division

Market

Segment/Market Position

Products

Customers

Anesthesiology

#1 in Europe, #2 in US

Anesthesia devices, vaporizers

Hospitals, clinics

Respiratory Care

#1 in Europe, #3 in US

Ventilators

Hospitals, clinics

Neonatal Care & Thermoregulation

#2 worldwide, #1 in Europe

Incubators, phototherapy

Hospitals, clinics

Monitoring, Systems & IT

#3 worldwide

Monitoring

Hospitals, clinics

Source: Company filings

Exhibit B:  Products – Safety Division

Market

Segment/Market Position

Products

Customers

Gas Detection Systems

#1 worldwide, #1 in Europe, #3 in US

Measuring systems, Dräger-Tubes

Oil/gas, chemical, mining

Alcohol Detection

#1 worldwide

Breathalyzers, Interlock vehicle device

Law enforcement, DUI offenders

Firefighter Breathing Apparatus

#2 worldwide

Integrated breathing protection

Fire departments, military diving, professional diving

Source: Company filings

Exhibit C:  Safety M&A

Target

Acquirer

Value (mm)

Completed

EBITDA

Industry

Sperian Protection (SPR FP)

Honeywell (HON)

 €       1,104

Oct-10

12x

Personal protection

General Monitors (private)

Mine Safety (MSA)

 $          280

Oct-10

10x

Gas monitoring & flame detection

Norcross Safety Products (private)

Honeywell (HON)

 $       1,200

May-08

11x

Personal protection

First Technology (FRS LN)

Honeywell (HON)

 $          630

Mar-06

12x

Gas sensing & detection

Zellweger Analytics (private)

Honeywell (HON)

 $          226

Jun-05

9x

Gas sensing & detection

Source: Company filings, news reports

Exhibit D:  Medical Financials (in millions Euros)

Medical division

2001

2002

2003

2004

2005

2006

2007

2008

2009

2010

2011

Order intake

       

   1,156

  1,275

  1,224

   1,277

   1,340

     1,442

   1,519

Orders on hand

       

      182

     209

     191

      220

      301

        281

      320

Net sales

    805

    848

    920

  1,023

   1,106

  1,239

  1,209

   1,244

   1,262

     1,472

   1,485

EBITDA

       60

       91

    103

     115

      124

     137

     130

      105

      111

        210

      216

margin

7%

11%

11%

11%

11%

11%

11%

8%

9%

14%

15%

EBIT

       39

       75

       85

        94

      101

     113

     104

         76

         77

        186

      192

margin

5%

9%

9%

9%

9%

9%

9%

6%

6%

13%

13%

Capital employed

     316

     329

    479

     563

      624

     657

     601

      642

      544

         515

      547

EBIT / Capital employed

12%

23%

18%

17%

16%

17%

17%

12%

14%

36%

35%

Exhibit E:  Safety Financials (in millions Euros)

Safety division

2001

2002

2003

2004

2005

2006

2007

2008

2009

2010

2011

Order intake

       

      573

    612

     736

      680

      666

        732

      805

Orders on hand

       

        83

    106

     200

      181

      141

        142

      143

Net sales

    425

    471

    477

     503

      558

    589

     638

      707

      677

        734

      803

EBITDA

       42

       53

       50

       58

        64

       74

       90

        83

        52

           82

        97

margin

10%

11%

11%

11%

12%

13%

14%

12%

8%

11%

12%

EBIT

       30

       40

       41

        37

         47

       55

       69

        61

         30

           61

         76

margin

7.1%

8.5%

8.6%

7.3%

8.5%

9.3%

10.9%

8.6%

4.5%

8.3%

9.5%

Capital employed

     156

     165

     157

     154

      191

     214

     220

      224

      190

         182

      193

EBIT / Capital employed

19%

24%

26%

24%

25%

26%

32%

27%

16%

34%

39%

Exhibit F:  Valuation (in millions Euros, except per share)

Segment

EBITDA

Multiple

Value

Medical

200

8x

  1,600

Safety

90

10x

     900

= Business value

  2,500

- Net debt & part. cert.

    (314)

= Equity value

  2,186

Per diluted share

 €  121

Note: Sum-of-the-parts EBITDA includes corporate overhead allocation.

Catalyst

 
    sort by    
      Back to top